Lavipharm S.A. logo

Lavipharm S.A. (BXA0)

Delisted
18 Mar 2026
XBER XBER
0. 94
0
0%
- Market Cap
- P/E Ratio
- Div Yield
0 Volume
0 Eps
0.94
Previous Close
Day Range
0.94 0.94
Year Range
0.69 0.97
Want to track BXA0 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

This company has been delisted from its primary exchange and is no longer publicly traded.
As a result, real-time price data, dividend updates, and corporate disclosures may no longer be available.

BXA0 Chart

Lavipharm S.A. (BXA0) FAQ

What does "Delisted" mean?

Lavipharm S.A. has been removed from the exchange and is no longer publicly traded.

What was the last recorded dividend?

No dividend payments were recorded prior to delisting.

How long did the company pay dividends?

The company did not have a dividend payment history.

Were there any stock splits?

The last recorded stock split occurred on Aug 01, 2022 with a ratio of 1:3.

What was the last known trading price?

The stock last traded at €0.94 on Mar 18, 2026 before being delisted.

Lavipharm S.A. Profile

Specialty Retail Industry
Consumer Discretionary Sector
Mr. Vassilis Baloumis CEO
XBER Exchange
- ISIN
DE Country
300 Employees
- Last Dividend
1 Aug 2022 Last Split
- IPO Date

Overview

Lavipharm S.A., founded in 1911 and headquartered in Paiania, Greece, is an esteemed entity in the global healthcare industry, focusing on the research, development, manufacture, import, marketing, sale, and wholesale of a broad spectrum of pharmaceutical, dermocosmetic, and healthcare products. Catering to both the Greek market and an international clientele, the company has established itself as a key player in providing healthcare solutions directly to physicians and pharmacists. With a rich legacy spanning over a century, Lavipharm S.A. combines its profound experience with innovative practices to bring effective healthcare solutions to the forefront of the industry.

Products and Services

  • Pharmaceutical Products for Specialized Fields
  • Lavipharm S.A. offers a diverse portfolio of pharmaceutical products targeting various critical areas of healthcare such as cardiology, oncology-urology, the central nervous system, and chronic pain management. This encompasses a range of medications designed to meet the therapeutic needs of patients, ensuring efficacy and safety across these core medical specialties.

  • Self-treatment Solutions
  • Understanding the growing trend towards self-care, the company provides a selection of products aimed at self-treatment. These are designed to empower individuals to manage their health proactively, with over-the-counter (OTC) options that are both accessible and reliable, fostering a culture of wellness and preventive care.

  • Prescription Medicines
  • Key to its product lineup, Lavipharm S.A. markets a variety of prescription medicines. These pharmaceuticals are developed based on rigorous research and adherence to industry standards, ensuring that healthcare professionals and patients have access to effective treatment options for a multitude of health concerns.

  • Over-the-Counter (OTC) Products
  • The range of over-the-counter (OTC) products offered by Lavipharm S.A. includes a vast selection of medications and health aids that can be purchased without a prescription. This segment enables consumers to address common health issues promptly and conveniently, enhancing the general wellbeing of the community.

  • LIFELAB CBD
  • Embracing the therapeutic potentials of cannabidiol (CBD), Lavipharm S.A. has ventured into the provision of LIFELAB CBD products. This line represents the company’s commitment to innovation in healthcare, offering scientifically-backed, CBD-infused solutions designed to support a range of health and wellness needs.

Contact Information

Address: 12, Agias Marinas Street, Paiania, Greece, 190 02
Phone: 30 210 66 91 000